| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
118.41(B) |
| Last
Volume: |
2,362,590 |
Avg
Vol: |
1,608,800 |
| 52
Week Range: |
$323.62 - $456.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
27,952 |
149,290 |
264,317 |
624,786 |
| Total Sell Value |
$12,512,803 |
$62,732,519 |
$104,276,665 |
$212,070,018 |
| Total People Sold |
8 |
12 |
14 |
18 |
| Total Sell Transactions |
9 |
42 |
65 |
132 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Silva Paul M |
SVP & Controller |
• – – |
2020-08-03 |
4 |
AS |
$276.00 |
$225,142 |
D/D |
(809) |
14,932 |
|
-18% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-08-03 |
4 |
OE |
$86.52 |
$69,995 |
D/D |
809 |
15,741 |
|
- |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-07-13 |
4 |
AS |
$284.56 |
$251,145 |
D/D |
(860) |
14,932 |
|
-24% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-07-13 |
4 |
OE |
$90.29 |
$77,649 |
D/D |
860 |
15,792 |
|
- |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2020-07-13 |
4 |
AS |
$284.28 |
$620,610 |
D/D |
(2,125) |
26,838 |
|
-24% |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2020-07-13 |
4 |
OE |
$90.29 |
$191,866 |
D/D |
2,125 |
28,963 |
|
- |
|
| Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2020-07-10 |
4 |
AS |
$291.19 |
$205,206 |
D/D |
(700) |
16,126 |
|
-28% |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-07-07 |
4 |
AS |
$300.00 |
$835,800 |
D/D |
(2,786) |
35,179 |
|
-25% |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-07-07 |
4 |
OE |
$155.57 |
$483,403 |
D/D |
2,786 |
37,965 |
|
- |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2020-06-30 |
4 |
AS |
$284.14 |
$9,383,304 |
D/D |
(32,792) |
2,261 |
|
-26% |
|
| Mckenzie Diana |
Director |
– • – |
2020-06-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
207 |
|
-2% |
|
| Mckenzie Diana |
Director |
– • – |
2020-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,435 |
1,435 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2020-06-02 |
4 |
AS |
$279.52 |
$269,298 |
D/D |
(952) |
5,695 |
|
-3% |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2020-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,398 |
6,647 |
|
- |
|
| Mcglynn Margaret G |
Director |
– • – |
2020-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
699 |
4,584 |
|
- |
|
| Carney Lloyd |
Director |
– • – |
2020-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,398 |
3,559 |
|
- |
|
| Garber Alan M |
Director |
– • – |
2020-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
699 |
5,890 |
|
- |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2020-05-29 |
4 |
D |
$282.74 |
$87,932 |
D/D |
(311) |
13,991 |
|
- |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2020-05-15 |
4 |
AS |
$274.37 |
$28,132 |
D/D |
(99) |
26,626 |
|
-3% |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-05-15 |
4 |
AS |
$276.35 |
$32,089 |
D/D |
(113) |
35,179 |
|
-3% |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2020-05-15 |
4 |
AS |
$273.91 |
$19,339 |
D/D |
(68) |
26,838 |
|
-3% |
|
| Silva Paul M |
SVP & Controller |
• – – |
2020-05-15 |
4 |
AS |
$275.71 |
$42,885 |
D/D |
(151) |
14,932 |
|
-3% |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-05-15 |
4 |
AS |
$274.67 |
$16,496 |
D/D |
(58) |
35,103 |
|
-3% |
|
| Tatsis Ourania |
EVP, Chief Regulatory Officer |
• – – |
2020-05-15 |
4 |
AS |
$276.35 |
$34,080 |
D/D |
(120) |
12,738 |
|
-3% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2020-05-15 |
4 |
AS |
$274.98 |
$23,318 |
D/D |
(82) |
28,902 |
|
-3% |
|
1777 Records found
|
|
Page 21 of 72 |
|
|
12.29 (2.77%) 
